Publisher Correction to: Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials.

Autor: Silverberg JI; Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA., Lynde CW; University of Toronto, Markham, ON, Canada.; Lynderm Research, Markham, ON, Canada., Abuabara K; Department of Dermatology, University of California San Francisco, San Francisco, CA, USA., Patruno C; Department of Health Sciences, Magna Graecia University, Catanzaro, Italy., de Benedetto A; Department of Dermatology, University of Rochester Medical Center, Rochester, NY, USA., Zhang H; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA., Thomas RB; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA., Bégo-Le-Bagousse G; Sanofi, Chilly-Mazarin, France., Khokhar FA; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA., Vakil J; Sanofi, Bridgewater, NJ, USA., Marco AR; Sanofi, Madrid, Spain., Levit NA; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA. noah.levit@regeneron.com.
Jazyk: angličtina
Zdroj: American journal of clinical dermatology [Am J Clin Dermatol] 2023 Jul; Vol. 24 (4), pp. 673. Date of Electronic Publication: 2023 May 17.
DOI: 10.1007/s40257-023-00784-6
Databáze: MEDLINE
Externí odkaz: